This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

X-linked Adrenoleukodystrophy / Addison-Schilder Disease부신백질디스트로피 [애디슨-쉴더]

Contents and key points
ItemDetails
A. Classification codesICD-10: E71.3 (Disorders of fatty-acid metabolism) | Special Copayment Reduction: V117 (ultra-rare disease, copayment exempt)
B. SynonymsX-linked adrenoleukodystrophy (X-ALD), Addison-Schilder disease, adrenoleukodystrophy, ABCD1 deficiency, X-linked ALD, adrenomyeloneuropathy (AMN), ALD
C. Adult onsetPossibility of first presentation in adulthood: high — adrenomyeloneuropathy (AMN) is an adult phenotype presenting after the 20s–30s with lower-limb spasticity, gait disturbance, and sphincter dysfunction. It is very common for X-ALD undiagnosed until adulthood to first present as AMN or adult cerebral ALD. About 40–45% of male patients show the AMN form.
1. History1923: first report by Siemerling and Creutzfeldt → 1970: Blaw names it ALD → 1976: Moser identifies VLCFA accumulation → 1980: X-linked inheritance confirmed → 1993: ABCD1 gene cloned → 1993: Lorenzo's Oil made into a film → 1990s: HSCT treatment established → 2017: Lenti-D gene therapy clinical trial
2. CausesPathogenic variants in the ABCD1 gene (Xq28) cause a defect in the peroxisomal VLCFA transport protein (ALDP). Impaired oxidation of very long-chain fatty acids (VLCFA: C24 and longer) → accumulation in brain white matter, adrenal cortex, and spinal cord.
3. GeneticsX-linked recessive inheritance. ABCD1 gene, Xq28. Mainly expressed in males. Mild AMN-like symptoms in approximately 20% of female carriers. More than 650 pathogenic variants reported.
4. General epidemiologyApproximately 1 in 17,000 male births (X-ALD overall). Same frequency worldwide, including Korea. Cerebral ALD, AMN, and Addison-only forms are the main phenotypes.
5. PathophysiologyALDP deficiency → blocked peroxisomal VLCFA beta-oxidation → accumulation of VLCFA (C26:0, C24:0) in plasma and tissues → brain white matter demyelination, adrenocortical hypofunction, spinal cord axonal degeneration.
6. SymptomsCerebral form: cognitive, behavioral, and learning abnormalities → rapid neurodegeneration. AMN: lower-limb spasticity, sphincter abnormalities, sexual dysfunction. Adrenal hypofunction: fatigue, skin hyperpigmentation, hypotension, hypoglycemia.
7. SignsMRI: signal abnormalities in the corpus callosum and occipital and parietal white matter (Loes score). Elevated plasma VLCFA (C26:0, C24:0/C22:0, and C26:0/C22:0 ratios). Adrenocortical hypofunction (low cortisol, high ACTH).
8. ScreeningNewborn screening: plasma VLCFA (C26:0) measurement or ABCD1 gene analysis. Molecular genetic testing if there is a family history. Included in NBS in some countries (e.g., the United States).
9. DiagnosisPlasma VLCFA profile (C26:0, ratios) measurement + ABCD1 gene analysis. Brain MRI (Loes score calculation). Adrenal function tests (cortisol, ACTH). Nerve conduction studies (AMN evaluation).
10. TreatmentCerebral ALD: early HSCT (allogeneic hematopoietic stem cell transplantation) or gene therapy (elivaldogene tavalentivec). Lorenzo's Oil (dietary therapy, VLCFA reduction). AMN: symptomatic treatment. Adrenal hypofunction: steroid replacement.
11. PrognosisCerebral ALD: vegetative state and death within a few years if untreated. Early HSCT (Loes ≤9, asymptomatic lesion stage) can halt progression. AMN: progresses slowly, but normal life expectancy possible. Female carriers may have mild AMN symptoms.
12. PreventionGenetic counseling, testing of female carriers, newborn screening (VLCFA or gene). Regular MRI monitoring of male patients (every 6–12 months). Periodic adrenal function testing.
13. ReferencesMoser HW et al. Adrenoleukodystrophy, 2000 … and 9 other papers

1. History

The first clinical description of X-linked adrenoleukodystrophy (X-ALD) dates back to 1923, by the German neuropathologists Siemerling and Creutzfeldt. They described a boy with progressive cerebral demyelinating lesions together with adrenal atrophy, a report later regarded as the first to capture the combined pathology of this disease. Similar cases continued to be reported sporadically after 1923, but decades were needed before it was recognized as an independent disease entity.

In 1970, the American neurologist Milton Blaw gave the disease the name 'adrenoleukodystrophy (ALD),' establishing it as an independent clinical entity. In 1973, Schaumburg et al. identified lamellar inclusions in the cerebral white matter by electron microscopy, describing the characteristic histopathology of the disease. In 1976, Moser et al. discovered marked accumulation of very long-chain fatty acids (VLCFA; especially C24:0 and C26:0) in the plasma and adrenal glands of ALD patients, laying the foundation for biochemical diagnosis. This discovery provided the basis for using plasma VLCFA measurement as a diagnostic and screening test.

In the 1980s, the mode of inheritance was established as X-linked recessive, and in 1993 Mosser et al. cloned the ABCD1 (ATP-binding cassette, subfamily D, member 1) gene, enabling understanding at the molecular level. ALDP (adrenoleukodystrophy protein), encoded by the ABCD1 gene, was found to be a transport protein of the peroxisomal membrane essential for the entry of VLCFA into the peroxisome and its oxidation. In 1992, Augusto Odone developed a dietary oil mixture of oleic acid and erucic acid (Lorenzo's Oil) to treat his son Lorenzo's ALD, and this story was made into the 1992 film Lorenzo's Oil directed by George Miller, greatly raising public awareness of ALD.

In terms of treatment, it was confirmed from the early 1990s that hematopoietic stem cell transplantation (HSCT) can halt the progression of cerebral ALD. Based on the 2017 study by Cartier et al., autologous hematopoietic stem cell gene therapy using a lentiviral vector (elivaldogene tavalentivec, Lenti-D) demonstrated efficacy in clinical trials and received US FDA approval in 2021. This gene therapy is attracting attention as an alternative treatment for patients with cerebral ALD who lack a suitable allogeneic donor. In Korea, it is designated as an ultra-rare disease (V117) under the Rare Disease Management Act.


2. Causes

The cause of X-linked adrenoleukodystrophy (X-ALD) is functional deficiency of the peroxisomal membrane transport protein ALDP (adrenoleukodystrophy protein) due to pathogenic variants in the ABCD1 gene, located on the long arm of the X chromosome (Xq28). The ABCD1 gene is approximately 21 kb long, consists of 10 exons, and encodes the 745-amino-acid ALDP. ALDP is a half-transporter of the ATP-binding cassette (ABC) transporter subfamily D, located in the peroxisomal membrane, and is responsible for transporting VLCFA-CoA esters into the peroxisomal matrix.

When ALDP is deficient, very long-chain fatty acids (VLCFA) with 22 or more carbons are not normally beta-oxidized in the peroxisome and accumulate intracellularly, particularly in myelin, the adrenal cortex, testes, spinal cord, and liver. Elevated plasma C26:0 (hexacosanoic acid) and C24:0 (tetracosanoic acid) and elevated C24:0/C22:0 and C26:0/C22:0 ratios are the characteristic biochemical abnormalities. VLCFA accumulation causes tissue damage through disruption of the lipid bilayer structure of cell membranes, mitochondrial dysfunction, induction of oxidative stress, and immune-mediated demyelinating responses.

Notably, even within a family carrying the same ABCD1 variant, very diverse phenotypes appear, including cerebral ALD, AMN, and isolated adrenal hypofunction. This means that the type of ABCD1 variant does not determine the phenotype, and genetic background (modifier genes), environmental factors, and individual differences in immune response are understood to play important roles in determining the phenotype. A hypothesis has also been proposed that other ABC transporters such as ABCD2 and ABCD3 may partially compensate for ABCD1 deficiency. To date, more than 650 different pathogenic ABCD1 variants have been reported, including missense, nonsense, deletion, insertion, and splicing variants.


3. Genetics

X-ALD follows an X-linked recessive mode of inheritance. The ABCD1 gene is located at the distal end of the long arm of the X chromosome (Xq28). Because males (XY) have only a single copy of the ABCD1 gene, a single pathogenic variant is enough for the disease to manifest. Females (XX) have a second normal ABCD1 allele and are mostly asymptomatic or mildly affected, but depending on skewed X-inactivation (lyonization), AMN-like symptoms (lower-limb spasticity, sphincter abnormalities) may appear in adulthood in approximately 20–30% of female carriers.

The ABCD1 gene is approximately 21 kb and consists of 10 exons, encoding the 745-amino-acid ALDP. More than 650 pathogenic variants have been identified to date, of which missense variants account for approximately 50%, frameshift or nonsense variants approximately 30%, deletions/insertions approximately 15%, and splicing variants approximately 5%. There is no specific founder mutation, and most variants are unique to individual families. Genotype-phenotype correlation is very low, and cerebral ALD and AMN can occur together even among brothers with the same variant.

When a family history is confirmed, carrier women can determine whether the fetus carries the ABCD1 variant through prenatal diagnosis (CVS or amniocentesis). Preimplantation genetic testing (PGT) is also technically possible. De novo variants occur in approximately 4–5%, in which case the disease occurs even without a family history. Molecular diagnosis of ABCD1 variants is performed by Sanger sequencing, NGS-based gene panels, WES, and WGS. If no single variant is found, exon-level deletions must be excluded by MLPA.


4. General epidemiology

X-ALD occurs at a frequency of approximately 1 in 17,000–20,000 male births, which is approximately 1:35,000 based on all births regardless of sex. According to data from the World Federation of Hemophilia (WFH) or similar rare disease organizations, there are estimated to be approximately 15,000–20,000 X-ALD patients worldwide. The disease is not concentrated in any particular ethnicity or region and occurs at the same frequency in all races worldwide.

The distribution of the main X-ALD phenotypes in male patients is as follows. Cerebral ALD (CALD): approximately 35–40% (childhood onset approx. 31–35%, adolescence approx. 4%, adulthood approx. 2–4%). Adrenomyeloneuropathy (AMN): approximately 40–45%. Addison-only form with isolated adrenal hypofunction: approximately 10–15%. Biochemical abnormality only without symptoms: approximately 5–10%. Approximately 20–30% of female carriers experience AMN-like symptoms, but cerebral ALD and severe adrenal hypofunction are rare.

Official epidemiological data in Korea are limited, but several dozen confirmed patients are estimated to be registered in Health Insurance Review & Assessment Service (HIRA) and rare disease registry data. VLCFA measurement is included in newborn screening programs in some countries (e.g., the United States), but it is not yet officially included in Korea's standard newborn screening panel, so most cases are diagnosed after clinical symptoms appear. In male patients, childhood cerebral ALD has a grave prognosis with rapid progression within a few years of diagnosis, whereas AMN progresses slowly from adulthood onward.


5. Pathophysiology

The core pathophysiology of X-ALD is impaired VLCFA oxidation in the peroxisome. Normally, very long-chain fatty acids (VLCFA) with 22 or more carbons are transported across the peroxisomal membrane into the peroxisomal matrix by ALDP (the ABCD1 protein) and then degraded by the peroxisomal beta-oxidation enzymes. In ABCD1 deficiency, VLCFA cannot enter the peroxisome, and intracellular VLCFA accumulates. Elevated plasma C26:0 and C24:0 concentrations and elevated C24:0/C22:0 and C26:0/C22:0 ratios reflect this.

VLCFA accumulation in the brain white matter causes demyelination and neuronal damage through complex pathophysiology. First, excess VLCFA is incorporated into the lipid bilayer structure of myelin, causing structural instability and abnormal signaling. Second, in cerebral ALD, a strong immune-mediated demyelinating response (neuroinflammation) is activated along with increased blood-brain barrier (BBB) permeability. Activation of reactive astrocytes and microglia, secretion of cytokines (TNF-α, IL-1β, IL-6), and infiltration of T cells and macrophages into lesions are characteristic. Third, oxidative stress (reactive oxygen species, ROS) increases, accelerating cell damage. These processes produce the characteristic brain MRI pattern that begins in the parieto-occipital white matter and progresses anteriorly.

In the adrenal cortex, VLCFA accumulation impairs the function of enzymes involved in glucocorticoid biosynthesis and promotes apoptosis of adrenocortical cells, resulting in primary adrenal insufficiency (Addison disease). In the spinal cord, axonal degeneration of the corticospinal tract and spinocerebellar tract causes the lower-limb spasticity and gait disturbance of AMN. The spinal cord lesions of AMN are explained mainly by direct axonal toxicity from VLCFA accumulation rather than immune mediation.


6. Symptoms

The clinical presentation of X-ALD is highly variable, and the phenotype can differ greatly even among individuals with the same ABCD1 variant. The main phenotypes are divided into childhood cerebral ALD (CCALD), adrenomyeloneuropathy (AMN), adult cerebral ALD (adult CALD), and the isolated adrenal hypofunction form.

Childhood cerebral ALD (CCALD): the age of onset is usually 3–10 years, beginning with decreased attention, behavioral abnormalities (hyperactivity, impulsivity), and declining academic performance in boys with previously normal development. If diagnosis is delayed, it progresses rapidly to visual and hearing impairment, seizures, gait ataxia, limb rigidity, dysphagia, and incontinence, reaching a vegetative state within a few years. Brain MRI shows characteristic signal abnormalities in the occipito-parietal white matter, with lesions beginning in the corpus callosum (splenium) and progressing anteriorly. CALD is the most severe X-ALD phenotype and, if untreated, progresses to death or a vegetative state within 2–4 years of onset.

Adrenomyeloneuropathy (AMN): a phenotype that presents gradually in adult men after their 20s–40s. Main symptoms are lower-limb spasticity, progressive gait disturbance, sensory abnormalities, bladder and bowel dysfunction (sphincter dysfunction), and sexual dysfunction. Upper-limb dysfunction and cerebellar symptoms may be added later. Brain MRI abnormalities appear in approximately 40–60% of male AMN patients, and about 20% of them progress to cerebral lesions. Female carriers (heterozygous females) with AMN may also show similar lower-limb spasticity and sensory abnormalities, but these are generally mild.

Adrenal hypofunction: adrenocortical hypofunction is present in approximately 70–80% of male X-ALD patients. Typical symptoms of primary adrenal hypofunction appear, such as fatigue, weight loss, increased skin hyperpigmentation, hypotension, hypoglycemia, nausea, vomiting, and abdominal pain. Adrenal hypofunction as the first presenting symptom is also reported in approximately 10–15%. Addisonian crisis (adrenal crisis) is life-threatening and requires immediate steroid replacement therapy.


7. Signs

Plasma VLCFA testing: the most important biochemical sign of X-ALD is elevated plasma very long-chain fatty acids (VLCFA). Elevated plasma C26:0 (hexacosanoic acid) concentration and elevated C24:0/C22:0 and C26:0/C22:0 ratios are characteristic. This test shows nearly 100% sensitivity in affected males, but only about 80–85% of female carriers are abnormal, so ABCD1 gene analysis is needed in carrier women. Blood erucic acid levels are used to monitor Lorenzo's Oil therapy.

Brain MRI: the most important imaging marker of CALD. Symmetric hyperintense lesions on T2-weighted and FLAIR images beginning in the posterior parietal-occipital white matter and the splenium of the corpus callosum are characteristic. The contrast enhancement pattern (gadolinium enhancement) indicates blood-brain barrier disruption and active inflammatory neural lesions and is important for assessing progression. The Loes score quantifies the extent and location of MRI lesions on a 10-point system and is used to determine HSCT indications and assess treatment response. Prognosis is best when HSCT is performed at a Loes score of 9 or lower, at the stage of MRI abnormalities with only mild neurological symptoms. In AMN, spinal cord MRI shows signal abnormalities in the corticospinal tract.

Adrenal function tests: serum cortisol (decreased), plasma ACTH (elevated), and the ACTH stimulation test (poor cortisol response) confirm adrenal hypofunction. Electrolyte abnormalities (hyponatremia, hyperkalemia) appear with mineralocorticoid deficiency. Nerve conduction studies are useful for quantifying corticospinal tract dysfunction and sensory nerve lesions in AMN.


8. Screening

Newborn screening for X-ALD is included in expanded newborn screening programs in some countries. In the United States, X-ALD has been on the federal Recommended Uniform Screening Panel (RUSP) since 2016, and newborn screening is performed in more than 40 states. The screening method uses plasma VLCFA measurement from dried blood spots (DBS) (specifically C26:0 lysophosphatidylcholine, C26:0-LPC). Among VLCFA measurements, C26:0-LPC is easily quantified by MS/MS, making it suitable for newborn screening.

When screening is positive, confirmatory testing includes a full plasma VLCFA profile (C26:0, C24:0, C22:0, ratios) and ABCD1 gene analysis. Genetic analysis confirms that the VLCFA elevation is caused by an ABCD1 variant and is also needed to distinguish it from other peroxisomal disorders. In female carriers, VLCFA levels may be normal, so carrier status cannot be confirmed by VLCFA measurement alone and ABCD1 gene analysis is essential. In Korea, X-ALD is currently not officially included in the standard newborn screening panel, so most cases are diagnosed by plasma VLCFA measurement after clinical symptoms appear. In at-risk groups with a family history (carrier mothers, affected brothers), early diagnosis is possible through molecular genetic testing.


9. Diagnosis

Diagnosis of X-ALD is made by combining plasma VLCFA measurement, brain MRI, and ABCD1 gene analysis on the basis of clinical suspicion. Measurement of the plasma VLCFA profile (quantification of C26:0, C24:0, and C22:0 and calculation of ratios) is the first-line biochemical diagnostic test. It is positive in nearly 100% of affected males, but 15–20% of female carriers may be normal.

ABCD1 gene analysis is performed by Sanger sequencing or an NGS-based panel. If only a single variant is found, MLPA or exon-level deletion analysis is added. Pathogenicity of identified variants is assessed with reference to ACMG criteria and existing reporting databases (such as the ABCD1 variant database). After diagnostic confirmation, brain MRI is repeated every 6–12 months to detect the appearance or progression of cerebral lesions early. Quantification of lesions using the Loes score is key to determining the timing of HSCT. Because the presence of contrast enhancement indicates the active inflammatory stage, imaging with gadolinium contrast is essential.

Adrenal function should be evaluated at diagnosis and regularly thereafter. Serum cortisol (measured at 8 a.m.), plasma ACTH, and the ACTH stimulation test (cortisol response 30 minutes after 250 mcg Synacthen IV) determine whether adrenal hypofunction is present. Neurological evaluation includes neuropsychological testing, nerve conduction studies (AMN evaluation), and auditory evoked potentials (evaluation of auditory damage in cerebral ALD). Spinal cord MRI is useful for evaluating corticospinal tract lesions in AMN.


10. Treatment

Treatment of X-ALD differs greatly by phenotype, and a tailored approach for each phenotype is needed.

Treatment of cerebral ALD (CALD): to date, the only proven treatments that can halt the progression of cerebral ALD are hematopoietic stem cell transplantation (HSCT) and gene therapy. HSCT has been shown to halt lesion progression and allow long-term stabilization when performed at an early or pre-symptomatic stage with a Loes score of 9 or less and no contrast enhancement. In the active inflammatory stage with contrast enhancement, transient worsening after HSCT is possible, so careful judgment is needed. Elivaldogene tavalentivec (Skysona), approved by the FDA in 2021, is a gene therapy in which the patient's own hematopoietic stem cells are transduced with a lentiviral vector carrying normal ABCD1 cDNA and then infused; it is an alternative when no suitable allogeneic donor is available.

Lorenzo's Oil: a 4:1 dietary oil mixture of oleic acid and erucic acid that can normalize plasma C26:0 levels. However, it cannot reverse brain lesions that have already developed or restore neurological function. It is used in some cases to prevent the development of brain lesions in patients identified by newborn screening or at the pre-symptomatic stage, but the evidence is insufficient, so it is not recommended for all patients.

Treatment of AMN: treatment of AMN is mainly symptomatic. Baclofen, tizanidine, and other muscle relaxants are used for lower-limb spasticity. Anticholinergics or beta-3 agonists are used for bladder dysfunction, and in severe cases intermittent self-catheterization is performed. Rehabilitation (physical therapy, occupational therapy) helps maintain function. Treatment of adrenal hypofunction: hydrocortisone (glucocorticoid) replacement therapy is standard. Fludrocortisone is added when mineralocorticoid deficiency is present. Education on stress dosing is essential to prevent adrenal crisis.


11. Prognosis

The prognosis of X-ALD differs dramatically by phenotype and timing of treatment. Childhood cerebral ALD (CCALD) has the gravest prognosis and, if untreated, leads to death or a vegetative state within an average of 2–4 years of onset. However, HSCT or gene therapy performed at an early stage with a Loes score of 9 or less and no contrast enhancement can effectively halt lesion progression and achieve long-term stabilization. In long-term follow-up of 10–20 years after HSCT, cases of lesion stabilization or slight improvement have been reported in some patients. However, because HSCT itself carries risks of transplant-related mortality (TRM) and graft-versus-host disease (GvHD), donor selection and pre-transplant conditioning are very important.

Adrenomyeloneuropathy (AMN) is a slowly progressive phenotype in which normal or near-normal life expectancy is possible. In the long term, however, lower-limb spasticity, gait disturbance, and bladder and bowel dysfunction may worsen and reduce quality of life. Because about 20% of AMN patients progress to adult cerebral lesions, periodic MRI monitoring is essential. Adrenal hypofunction can be managed effectively with steroid replacement therapy, but untreated adrenal crisis is life-threatening. AMN-like symptoms may appear in about 20–30% of female carriers but are generally mild, and progression to cerebral ALD is very rare.


12. Prevention

Primary prevention of X-ALD is achieved through genetic counseling and carrier screening. When an X-ALD patient is identified in a family, carrier testing by ABCD1 gene analysis is performed in at-risk female relatives (mother, sisters, maternal aunts, etc.). When a carrier woman becomes pregnant, whether the fetus carries the ABCD1 variant can be determined by prenatal testing (CVS or amniocentesis), and implantation of affected embryos can also be avoided through PGT. Newborn screening (plasma C26:0-LPC MS/MS measurement) enables diagnosis at the pre-symptomatic stage, providing the opportunity for early HSCT upon conversion to cerebral ALD.

Secondary prevention consists of early detection and prevention of conversion to cerebral ALD and of adrenal crisis in confirmed patients. In asymptomatic males carrying an ABCD1 variant (especially children), brain MRI and neuropsychological testing are performed every 6–12 months to detect conversion to cerebral ALD early. Regular testing for adrenal hypofunction (cortisol, ACTH) allows early detection of asymptomatic adrenal hypofunction and initiation of steroid replacement therapy. In AMN patients, active symptomatic treatment such as rehabilitation, assistive devices, and bladder management slows functional decline and maintains quality of life. Patients and families must be familiar with the stress-dose steroid plan for preventing adrenal crisis in stressful situations such as surgery, infection, and trauma.


13. References

  1. Moser HW, et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis. 1992;15(4):645-664. PMID: 1528027
  2. Engelen M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51. PMID: 22889154
  3. Bergner CG, et al. Adrenoleukodystrophy: biology, pathology and treatment. Brain Pathol. 2021;31(6):e12916. PMID: 34414580
  4. Cartier N, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. Science. 2009;326(5954):818-823. PMID: 19892975
  5. Loes DJ, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994;15(9):1761-1766. PMID: 7847225
  6. Mahmood A, et al. Long-term outcomes after allogeneic hematopoietic cell transplantation for cerebral adrenoleukodystrophy. Biol Blood Marrow Transplant. 2007;13(9):1075-1085. PMID: 17669603
  7. Eichler F, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630-1638. PMID: 29068162
  8. Waterham HR, et al. Human disorders in fatty acid synthesis. Prog Lipid Res. 2016;61:38-57. PMID: 26549794
  9. Raymond GV, et al. Treatment of adrenoleukodystrophy. Curr Opin Neurol. 2019;32(3):372-379. PMID: 30870176
  10. Turk BR, et al. X-linked adrenoleukodystrophy: pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80(1):52-72. PMID: 31710749